Tags

Type your tag names separated by a space and hit enter

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
Pharmacoeconomics. 2020 09; 38(9):981-994.P

Abstract

BACKGROUND

Paroxysmal nocturnal hemoglobinuria, characterized by intravascular hemolysis and venous thrombosis, can be managed with eculizumab, an inhibitor of the complement system; however, patients may periodically experience breakthrough hemolysis. Ravulizumab is a newly approved treatment for paroxysmal nocturnal hemoglobinuria that may reduce breakthrough hemolysis risk, thus improving health-related quality of life and reducing treatment costs.

OBJECTIVE

The objective of this study was to compare the costs and benefit of treatment with ravulizumab vs eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria, from a US payer perspective.

METHODS

A cost-utility analysis was conducted using a semi-Markov model, informed by clinical experts. Lifetime costs and benefit (quality-adjusted life-years) (both discounted at 3% per annum) and incremental cost-effectiveness ratios were estimated, over a lifetime horizon. Results are reported for an entire treated population and subgroups of eculizumab treatment history. Scenario analyses were characterized by assumptions of non-inferiority between treatments, in terms of breakthrough hemolysis incidence and blood transfusion requirements, and of variations in eculizumab dosing adjustments used in response to breakthrough hemolysis.

RESULTS

In the base-case analysis for the overall population, there was a positive impact on health-related quality of life (quality-adjusted life-year gain of 1.67) and costs were lower (- $1,673,465), for ravulizumab vs eculizumab. This led to a negative incremental cost-effectiveness ratio (- $1,000,818, indicating cost savings per quality-adjusted life-year gained). Health-related quality-of-life improvement and cost savings were also observed in all cohorts and scenario analyses.

CONCLUSIONS

In adults with paroxysmal nocturnal hemoglobinuria, ravulizumab is associated with improved health-related quality of life and provides a large cost saving from the perspective of a US payer, when compared with eculizumab.

Authors+Show Affiliations

Medicus Economics, Boston, MA, USA.Medicus Economics, Boston, MA, USA.Medicus Economics, Boston, MA, USA.Medicus Economics, Boston, MA, USA.Alexion Pharmaceuticals, Boston, MA, USA.Alexion Pharmaceuticals, Boston, MA, USA. Ioannis.Tomazos@alexion.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32519233

Citation

O'Connell, Thomas, et al. "Cost-Utility Analysis of Ravulizumab Compared With Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria." PharmacoEconomics, vol. 38, no. 9, 2020, pp. 981-994.
O'Connell T, Buessing M, Johnson S, et al. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. Pharmacoeconomics. 2020;38(9):981-994.
O'Connell, T., Buessing, M., Johnson, S., Tu, L., Thomas, S. K., & Tomazos, I. (2020). Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. PharmacoEconomics, 38(9), 981-994. https://doi.org/10.1007/s40273-020-00929-z
O'Connell T, et al. Cost-Utility Analysis of Ravulizumab Compared With Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria. Pharmacoeconomics. 2020;38(9):981-994. PubMed PMID: 32519233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. AU - O'Connell,Thomas, AU - Buessing,Marric, AU - Johnson,Scott, AU - Tu,Lufei, AU - Thomas,Simu K, AU - Tomazos,Ioannis, PY - 2020/6/11/pubmed PY - 2020/6/11/medline PY - 2020/6/11/entrez SP - 981 EP - 994 JF - PharmacoEconomics JO - Pharmacoeconomics VL - 38 IS - 9 N2 - BACKGROUND: Paroxysmal nocturnal hemoglobinuria, characterized by intravascular hemolysis and venous thrombosis, can be managed with eculizumab, an inhibitor of the complement system; however, patients may periodically experience breakthrough hemolysis. Ravulizumab is a newly approved treatment for paroxysmal nocturnal hemoglobinuria that may reduce breakthrough hemolysis risk, thus improving health-related quality of life and reducing treatment costs. OBJECTIVE: The objective of this study was to compare the costs and benefit of treatment with ravulizumab vs eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria, from a US payer perspective. METHODS: A cost-utility analysis was conducted using a semi-Markov model, informed by clinical experts. Lifetime costs and benefit (quality-adjusted life-years) (both discounted at 3% per annum) and incremental cost-effectiveness ratios were estimated, over a lifetime horizon. Results are reported for an entire treated population and subgroups of eculizumab treatment history. Scenario analyses were characterized by assumptions of non-inferiority between treatments, in terms of breakthrough hemolysis incidence and blood transfusion requirements, and of variations in eculizumab dosing adjustments used in response to breakthrough hemolysis. RESULTS: In the base-case analysis for the overall population, there was a positive impact on health-related quality of life (quality-adjusted life-year gain of 1.67) and costs were lower (- $1,673,465), for ravulizumab vs eculizumab. This led to a negative incremental cost-effectiveness ratio (- $1,000,818, indicating cost savings per quality-adjusted life-year gained). Health-related quality-of-life improvement and cost savings were also observed in all cohorts and scenario analyses. CONCLUSIONS: In adults with paroxysmal nocturnal hemoglobinuria, ravulizumab is associated with improved health-related quality of life and provides a large cost saving from the perspective of a US payer, when compared with eculizumab. SN - 1179-2027 UR - https://www.unboundmedicine.com/medline/citation/32519233/Cost_Utility_Analysis_of_Ravulizumab_Compared_with_Eculizumab_in_Adult_Patients_with_Paroxysmal_Nocturnal_Hemoglobinuria_ L2 - https://dx.doi.org/10.1007/s40273-020-00929-z DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.